Homology Medicines Inc
Change company Symbol lookup
Select an option...
FIXX Homology Medicines Inc
SOFI SoFi Technologies Inc
MBOT Microbot Medical Inc
OLP One Liberty Properties Inc
GNT-A Gamco Natural Resources Gold & Income Trust
AGRI AgriFORCE Growing Systems Ltd
LEN Lennar Corp
PEPL PepperLime Health Acquisition Corp
LOCL Local Bounti Corp
STVN Stevanato Group SpA
Go

Health Care : Biotechnology | Small Cap Blend
Company profile

Homology Medicines, Inc. is a clinical-stage genetic medicines company focused on providing treatment for rare genetic diseases. The Company’s clinical programs include HMI-102, is an investigational gene therapy candidate in clinical development for the treatment of adult patients with phenylketonuria (PKU); HMI-103, which is an investigational gene editing candidate in clinical development for the treatment of patients with PKU, and HMI-203, which is an investigational gene therapy candidate in clinical development for the treatment of patients with mucopolysaccharidosis type II (MPS II), or Hunter syndrome. Additionally, the Company is developing a gene therapy candidate, HMI-104, from its GTx-mAb platform for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH), and conducting research in other diseases, including metachromatic leukodystrophy (MLD). Its platform is designed to utilize human hematopoietic stem cell derived adeno-associated virus vectors.

Closing Price
$1.51
Day's Change
0.01 (0.67%)
Bid
--
Ask
--
B/A Size
--
Day's High
1.54
Day's Low
1.46
Volume
(Light)
Volume:
100,126

10-day average volume:
197,508
100,126

Company Profile

Homology Medicines, Inc. is a clinical-stage genetic medicines company focused on providing treatment for rare genetic diseases. The Company’s clinical programs include HMI-102, is an investigational gene therapy candidate in clinical development for the treatment of adult patients with phenylketonuria (PKU); HMI-103, which is an investigational gene editing candidate in clinical development for the treatment of patients with PKU, and HMI-203, which is an investigational gene therapy candidate in clinical development for the treatment of patients with mucopolysaccharidosis type II (MPS II), or Hunter syndrome. Additionally, the Company is developing a gene therapy candidate, HMI-104, from its GTx-mAb platform for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH), and conducting research in other diseases, including metachromatic leukodystrophy (MLD). Its platform is designed to utilize human hematopoietic stem cell derived adeno-associated virus vectors.

Valuation Ratios

Price/Earnings (TTM)
--
Price/Sales (TTM)
27.06x
Price/Book (MRQ)
0.42x
Price/Cash Flow (TTM)
29.57x
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

No historic growth available.

Short Interest

November 2022
Current Month
1.1M
Previous Month
1.1M
Percent of Float
2.04%
Days to Cover
7.3858 Days

Share Information

FIXX is in a share class of common stock
Float
52.2M
Shares Outstanding
57.5M
Institutions Holding Shares
108
49.92%

Financial Statements

Balance sheet

Values displayed are in thousands.

Income statement

Values displayed are in thousands.

Cash flow

Values displayed are in thousands.

Company Officers

  • Arthur O. TzianabosChmn.
  • Albert SeymourPres.
  • W. Bradford SmithCFO
  • Michael Lee BlumOther
  • Paul AllowaySecy.

Address

Insider Trading

No insider trading activity.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2022. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.